SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vasomedical Inc.
VASO 0.170+6.3%Dec 5 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TradeOfTheDay who wrote (710)11/12/1997 6:17:00 PM
From: Fred Levine  Read Replies (1) of 1605
 
Bev--Your post was right on target. I have little to add except emphasize one of your points-- how market-driven medicine is now. There will be immediate circulation (pun intended) of the results to angina patients about EECP. They will pressure their insurance comapnies, who, in turn, will see the cost benefits. Right now, I am sure every one of the centers involved in the MUST-EECP study are getting many calls. The market must expand.

Not to be cynical, but I am glad there are empirical data supporting EECP, because, unfortunately, people with angina will go after treatments of dubious efficacy.

good investing--fred
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News